ArticleBlood purification2026
Feasibility Study of a Smartphone App and Web Portal for Remote Monitoring of Chronic Kidney Disease and Peritoneal Dialysis Populations: A Mixed-Method Study.
Article in Blood purification, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionRemote patient monitoring facilitates the management of chronic conditions like chronic kidney disease (CKD) and home-based peritoneal dialysis (PD). This study assessed the acceptance of a remote monitoring application in CKD and PD patients.
methodsIt was a single-center study at Singapore General Hospital from December 2021 to February 2023, recruiting CKD and PD patients. Patients were followed up for up to 6 months. The Viva Konnect patient app allowed users to record vitals with a Bluetooth-enabled device, log medication schedule, track symptoms, log diet, and monitor PD therapy.
resultsA total of 35 participants (13 CKD, 22 PD) enrolled; 8 (5 CKD, 3 PD) dropped out, leaving 27 (8 CKD, 19 PD) who completed the study. Among those who completed the study, 56% met the app acceptance criteria - defined as CKD patients logging data at least twice per week and PD patients at least once daily. Acceptance rates were 47.4% for PD and 75.0% for CKD. PD patients used the app a median of 6.7 (IQR: 1.8-16.5) times per week, spending 6.9 (IQR: 2.2-12.1) minutes per session. CKD patients used it a median of 6.2 (IQR: 2.6-6.7) times per week, with a median session time of 4.7 (IQR: 1.7-7.7) minutes. The median percentage of vitals recorded via smart companion devices was 52.9% (IQR: 26.7-82.2) for PD patients and 83.4% (IQR: 78.8-94.4) for CKD patients. Interviews identified three key themes that affected the usage: communication, convenience, and clarity.
conclusionOverall app usage was moderate, with the CKD patient population showing better app acceptance than the PD population. To improve the usage and overall engagement, future app development should incorporate two-way communication with clinicians, a reduced burden of data recording, and better integration into established clinical workflows.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.